 |
 |
| Subtype selectivity of B1 blockers2,3 | |
| Propranolol | Two Fold B2 selective |
| Atenolol | 35 flod B1 selective |
| Betaxolol | 35 fold B1 selective |
| Bisoprolol (Valvozid®) | 75-fold B1 selectivity |
Related to the affinity for B2 receptors4 |
|
| Propranolol | No B1 selectivity |
| Carvedilol | No B1 selectivity |
| Atenolol | 6-fold B1 selectivity |
| Metoprolol | 6-fold B1 selectivity |
| Betaxolol | 7-fold B1 selectivity |
| Bisoprolol (Valvozid®) | 19-fold B1selectivity |
B1 Selectivity of Bisoprolol [Valvozid®] is best among the rest
Which ensures that with Bisoprolol [Valvozid®] treatment, the B2 receptors in different organs will remain unaffected in therapeutic doses and beyond.
Offers excellent pharmacokinetic Profile
Bisoprolol: Comparison to B1- selective B-blockers
|
|||||
| Criteria | Bisoprolol |
Atenolol | Metoprolol | Acebutolol | Celiprolol |
| Plasma elimination half-life(h | 10-12 |
6 -9 | 3-4 | 7-13 | 5 |
| Absorption (%)l | >99 |
50 | >95 | 70 | 50 |
| First-pass effect | - |
- | + | + | - |
| Bioavailability (% | 88 |
50 | 50 | 40-60 | 50* |
| Protein binding (%) | 30 |
3 | 12 | 11-25 | 25 |
| Active metabolites | - | - | - | + | - |
| Balanced clearance | + | - | - | - | - |
| *dose-dependent | Borchard U.B Rezeptorenblocker, Klinik Und Praxis, Aesopus Veriage 1998. | ||||
|
|
|
|
|
|
Giving excellent clinical profile
- High bioavailability giving therapeutic reliability and safety.
- Reliable once daily dose.
- Balanced clearance with no active metabolites so no need for dosage adjustment in patients with impaired renal and liver function
In two double-blind randomized studies, the dose dependent efficacy of bisoprolo (Valvozid®) , using doses 5-20 mg once daily, has been confirmed.
Bisoprolol: Dose-dependent blood
pressure reduction in hypertensives |
 |
In patients with essential hypertension having an initial diastolic blood pressure of 90- 120 mm Hg, bisoprolol (Valvozid®) reduced blood pressure approximately in proportion to the dose
Equally effective in all age Groups
Bisoprolol: Responder rate in Hypertension in dependence on age after 8 weeks of treatment |
 |
Bisoprolol (Valvozid®) normalized the diastolic blood pressure (to 90mm Hg or below) in 80% of hypertensive patients over 60 years of age.
Safe in Diabetic Patients
Bisoprolol [Valvozid] has been found to have no negative effects on glucose metabolism in either healthy volunteers9 or diabetic patients 10
Bisoprolol: Responder rate in Hypertension in dependence on age after 8 weeks of treatment |
 |
Glucose metabolism in diabetic patients
The potential effects of bisoprolo on insulin sensitivity have also been investigated. Glucose uptake is used as an index of insulin sensitivity. Bisoprolo [Valvozid®] shows no negative effects on glucose uptake, indicating that it is unlikely to provoke or exacerbate insulin resistance.11
Unlike other B1 blocker no dosage adjustment of Bisoprolol[Valvozid®] is required for diabetic patients.
Safe in Hyperlipidimic Patients
In a long term randomized comparative study bisoprolol [Valvozid®] affected triglycerides less than Propranolol and Atenolol and produced no significant changes in HDL , LDL , or total cholestrol 1.
Bisoprolol:b1- selectivity and lipid metabolism in long - term therapy.
|
 |
Due to lipid neutrality of bisoprolol [Valvozid®], no increase in atherogenic risk factory.
In Hypertension, CHF & Angina
|
|
|
- For Best B1 Selectivity
- For the achievement of treatment objectives.
- For Better efficacy and convenience
- For All Age Groups
- No Pressure of Diabetes While Prescribing in Diabetic patients.
